XOMA Corp License Agreements
18 Contracts & Agreements
- License Agreement, dated June 10, 2015, between ObsEva, SA and Ares Trading S.A (Filed With SEC on March 9, 2023)
- License Agreement, dated July 26, 2021, between ObsEva, SA and Organon International GmbH (Filed With SEC on March 9, 2023)
- License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience,... (Filed With SEC on November 3, 2022)
- License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG (Filed With SEC on November 3, 2022)
- IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG (Filed With SEC on November 3, 2022)
- Amendment No. 1, dated July 24, 2020, to the Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") and Sesen Bio, Inc (Filed With SEC on March 10, 2021)
- Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") Sesen Bio, Inc. and (formerly Viventia Biotech Inc.) (Filed With SEC on March 10, 2021)
- License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 (this exhibit was previously filed under confidential treatment... (Filed With SEC on November 5, 2020)
- Amendment No. 2, dated January 7, 2019, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio) (Filed With SEC on March 7, 2019)
- Amendment No. 1, dated March 30, 2018, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio, Inc.) (Filed With SEC on May 9, 2018)
- License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio) (Filed With SEC on March 7, 2018)
- License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG (Filed With SEC on November 6, 2017)
- IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG (Filed With SEC on November 6, 2017)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 9, 2016)
- LICENSE AGREEMENT by and between XOMA (US) LLC and NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. Table of Contents (continued) (Filed With SEC on November 6, 2015)
- First Amendment, dated October 28, 2014, to the License Agreement between XOMA (US) LLC (assigned to it by XOMA Ireland Limited) and BP Biofuels Advanced Technology Inc.... (Filed With SEC on November 6, 2014)
- [*] indicates that a confidential portion of the text of this agreement has been omitted. AMENDED ANDRESTATED LICENSE AGREEMENT (Filed With SEC on March 8, 2007)
- LICENSE AGREEMENT (Filed With SEC on August 8, 2005)
